As tau-PET has shown high performance in discriminating AD from non-AD neurodegenerative diseases, it is expected to have added value over current diagnostic processes in patients with residual diagnostic uncertainty after routine diagnostic work-up. This evidence concerns the gene MAPT and Alzheimer disease.